Kristen Degroff
Primary Care · Paw Paw, MINPI 1376078782
Payments from drug & device makers
Across 64 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$266
- Pfizer$203
- Lilly USA, LLC$126
- Merck$86
- Inspire Medical Systems, Inc.$58
- Otsuka America Pharmaceutical, Inc.$57
- plus $508 from 19 others
What the payments were for
- Food & beverage$1,304100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $266 |
| Pfizer | 17 | $203 |
| Lilly USA, LLC | 6 | $126 |
| Merck | 4 | $86 |
| Inspire Medical Systems, Inc. | 1 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Novo Nordisk | 3 | $46 |
| Lundbeck LLC | 2 | $45 |
| Mylan Specialty L.p. | 2 | $45 |
| Dexcom, Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Abbott | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Insulet Corporation | 1 | $31 |
| AbbVie | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Amgen | 1 | $16 |
| Novartis | 1 | $16 |
| Organon | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,304 in reported general payments places this provider in the 70th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 14 | $21,585 |
| TrulicityDulaglutide | 18 | $18,331 |
| EliquisApixaban | 11 | $15,618 |
| FarxigaDapagliflozin Propanediol | 14 | $14,732 |
| Repatha SureclickEvolocumab | 19 | $9,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,224 |
| Atorvastatin Calcium | 233 | $3,716 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,339 |
| Levothyroxine Sodium | 160 | $1,958 |
| Rosuvastatin Calcium | 92 | $1,633 |
| Ezetimibe | 31 | $1,154 |
| Lisinopril | 108 | $1,026 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $970 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 65 | $967 |
| Omeprazole | 46 | $797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $126 | $39,91532 claims |
| PfizerEliquis | $203 | $15,61811 claims |
| AstraZenecaFarxiga | $266 | $14,73214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 primary care providers in Michigan.
Other primary care in Paw Paw
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.